PT - JOURNAL ARTICLE AU - Claudia Ottka AU - Katariina Vapalahti AU - Ann-Marie Määttä AU - Nanna Huuskonen AU - Sinikka Sarpanen AU - Liisa Jalkanen AU - Hannes Lohi TI - Elevated blood creatinine -a biomarker of renal function-associates with multiple metabolic perturbations in dogs AID - 10.1101/2020.05.06.078063 DP - 2020 Jan 01 TA - bioRxiv PG - 2020.05.06.078063 4099 - http://biorxiv.org/content/early/2020/05/07/2020.05.06.078063.short 4100 - http://biorxiv.org/content/early/2020/05/07/2020.05.06.078063.full AB - BACKGROUND Renal diseases, such as chronic kidney disease (CKD) are common in dogs. While the kidneys have multiple important metabolic functions, the occurrence of metabolic disturbances in canine renal diseases has not been extensively studied.OBJECTIVES To identify metabolic changes in blood samples exhibiting elevated blood creatinine, indicating reduced renal filtration.ANIMALS Samples consisted of clinical samples analysed by a 1H NMR-based metabolomics platform. The case group included 23 samples with creatinine > 125 μmol/l, and the control group 873 samples with creatinine within the reference interval.METHODS Biomarker association with elevated creatinine was evaluated utilizing three statistical approaches: Wilcoxon rank-sum test and logistic regression analysis (FDR-corrected p-values), and classification using random forest. Means of the biomarkers were compared to reference intervals. A heatmap and histograms visualized the differences.RESULTS The levels of citrate, tyrosine, branched-chain amino acids, valine, leucine, albumin, linoleic acid % and the ratio of phenylalanine to tyrosine differed significantly both in the Wilcoxon test and logistic regression, acetate levels only in Wilcoxon test and docosapentaenoic acid % only in logistic regression (p <. 05). The ten most significant markers in random forest corresponded to the Wilcoxon test, supplemented with alanine.CONCLUSIONS AND CLINICAL IMPORTANCE This study identified multiple metabolic changes associated with elevated blood creatinine, including prospective diagnostic markers and therapeutic targets. The NMR metabolomics test is a promising tool for improving diagnostics and management of canine renal diseases. Further research is needed to verify the association of these changes to the canine patient’s clinical state.Competing Interest StatementThe study was funded by PetBIOMICS Ltd and the Academy of Finland (308887). CO is an employee, KV a previous employee, and HL is an owner and the Chairman of the Board of PetBIOMICS Ltd. AMM is the CEO, and NH a member of board of Movet Ltd. SS is an owner and CEO of Kuopion Elainlaakarikeskus Ltd. LJ is an owner and chairman of board of Pienelainvastaanottoo Punaturkki Ltd.